Introduction The coronavirus disease 2019 (COVID-19) first emerged in December 2019 in Wuhan City, Hubei, China, following reports of several pneumonia cases with unknown aetiology agent. Roughly 19.5 million infections and more than 700,000 deaths have been reported worldwide by the early of August 2020. Remdesivir is a nucleotide analogue which inhibits viral RNA polymerase and consequently disrupts viral replication. This drug also has broad antiviral activities. Remdesivir has been demonstrated to possess prophylactic and therapeutic activity against MERS-CoV in a rhesus-macaque model with lower viral replication and lung damage and the eventual improved clinical symptoms. Objective This review aims to summarise and synthesise published data evaluating remdesivir and COVID-19. Our primary aim is the effect and safety of remdesivir among COVID-19 patients. Methods [Refer to Poster]. Results [Refer to Poster]. Conclusion We found a paucity of high-quality clinical trials in relation to invitro, in-vivo and non-randomised studies, and so the quality of evidence to inform clinical practice is still not strong. The current evidence-base needs to be consolidated with the publication of more clinical trials with bigger cumulative samples, to the point where optimal information size is reached. Due to insufficient data, we are unable to determine further the applicability of the findings to all COVID patients, that is, adults and children. The high percentage of adverse effects in RCTs among adults and children need to be investigated further.